Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Beyond Air, Inc. XAIR

Healthcare  —  Medical Devices
2.85 (0.32) (10.09%) as of 25 Sep
Market cap
$3.1M
P/E
0.0×
Revenue Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Beyond Air, Inc. (XAIR) Business Profile

Updated before January 2025

Company Overview

Beyond Air, Inc. (NASDAQ: XAIR) is a medical device and biopharmaceutical company that specializes in the development and commercialization of innovative technologies for the treatment of respiratory diseases and other medical conditions. Founded in 2011, the company is headquartered in Garden City, New York, with additional operations in Israel. Beyond Air is led by a team of experienced executives, including CEO Steve Lisi, who has extensive expertise in the healthcare and medical device industries. The company’s mission is to revolutionize the treatment of respiratory conditions by leveraging its proprietary technologies and innovative approaches.

Core Business Segments

LungFit® System

The LungFit® system is Beyond Air’s flagship product and represents a breakthrough in the delivery of nitric oxide (NO) for therapeutic purposes. Unlike traditional methods that rely on high-pressure cylinders, the LungFit® system generates nitric oxide directly from ambient air, eliminating the need for bulky and potentially hazardous gas tanks. This technology is designed to treat a variety of respiratory conditions, including:

  • Persistent Pulmonary Hypertension of the Newborn (PPHN): A life-threatening condition in newborns that affects oxygenation.
  • Bronchiolitis: A common respiratory infection in infants and young children.
  • Severe Viral Pneumonia: Including conditions caused by respiratory viruses such as COVID-19.

Nitric Oxide Therapy

Beyond Air is also exploring the use of nitric oxide therapy for applications beyond respiratory diseases. The company is conducting clinical trials to evaluate the efficacy of NO in treating:

  • Chronic Obstructive Pulmonary Disease (COPD): A progressive lung disease that causes breathing difficulties.
  • Nontuberculous Mycobacteria (NTM) Infections: A rare but serious condition that affects the lungs.

Biopharmaceutical Initiatives

Beyond Air is actively involved in biopharmaceutical research to expand the therapeutic applications of its nitric oxide technology. The company is investigating the potential of NO in oncology and other non-respiratory medical fields.

Business Model

Beyond Air operates on a hybrid business model that combines medical device sales with biopharmaceutical research and development. The company generates revenue through:

  • Product Sales: The LungFit® system and related accessories.
  • Licensing Agreements: Partnerships with other healthcare companies to commercialize its technologies.
  • Clinical Trials and Grants: Funding from research initiatives and government grants.

This diversified approach allows Beyond Air to mitigate risks associated with reliance on a single revenue stream while fostering innovation and growth.

Strategic Direction

Beyond Air is focused on expanding its market presence and developing new applications for its nitric oxide technology. Key strategic initiatives include:

  • Global Expansion: The company aims to secure regulatory approvals in additional markets, including Europe and Asia.
  • Pipeline Development: Beyond Air is investing in clinical trials to explore new indications for nitric oxide therapy, such as oncology and infectious diseases.
  • Sustainability Goals: By eliminating the need for high-pressure gas cylinders, the LungFit® system reduces the environmental impact of nitric oxide delivery.
  • Partnerships and Collaborations: Beyond Air is actively seeking partnerships with healthcare providers and pharmaceutical companies to accelerate the adoption of its technologies.

Competitive Landscape

Beyond Air operates in a highly competitive market that includes both established medical device companies and emerging biopharmaceutical firms. Key competitors include:

  • Mallinckrodt Pharmaceuticals: A leading provider of nitric oxide delivery systems.
  • Vapotherm, Inc.: Specializes in high-flow oxygen therapy devices.
  • Novartis AG: A global pharmaceutical company with a focus on respiratory diseases.
  • Other Startups: Smaller companies developing innovative respiratory therapies.

Despite the competition, Beyond Air differentiates itself through its proprietary technology, which offers significant advantages in terms of safety, convenience, and cost-effectiveness.

Risk Factors

While Beyond Air has significant growth potential, it also faces several risks, including:

  • Regulatory Challenges: Delays in obtaining regulatory approvals could impact product launches.
  • Market Dependence: The company’s success is heavily reliant on the adoption of the LungFit® system.
  • Supply Chain Disruptions: Global supply chain issues could affect the production and distribution of its devices.
  • Competition: Intense competition from established players and new entrants could limit market share.
  • Financial Risks: As a relatively young company, Beyond Air may face challenges in achieving profitability.

Recent Developments

Beyond Air has made significant progress in recent years, including:

  • FDA Approval: The LungFit® PH system received FDA approval for the treatment of PPHN in 2022.
  • Clinical Trials: Ongoing studies to evaluate the efficacy of nitric oxide therapy in treating COPD and NTM infections.
  • Partnerships: Collaborations with leading healthcare providers to expand the adoption of the LungFit® system.
  • COVID-19 Response: Development of nitric oxide-based therapies for severe viral pneumonia caused by COVID-19.

Investment Considerations

Strengths

  • Innovative Technology: The LungFit® system offers a safer, more convenient, and cost-effective alternative to traditional nitric oxide delivery methods.
  • Diverse Applications: Beyond Air’s technology has potential applications in multiple medical fields, including respiratory diseases, oncology, and infectious diseases.
  • Strong Leadership: Experienced management team with a proven track record in the healthcare industry.

Risks

  • Regulatory and Market Risks: Dependence on regulatory approvals and market adoption.
  • Financial Uncertainty: Potential challenges in achieving profitability and sustaining long-term growth.
  • Competitive Pressure: Intense competition from established players and new entrants.

Conclusion

Beyond Air, Inc. is a pioneering company at the forefront of nitric oxide-based therapies. With its innovative LungFit® system and a robust pipeline of clinical trials, the company is well-positioned to address unmet medical needs in respiratory and other diseases. While challenges remain, Beyond Air’s unique technology, strategic initiatives, and experienced leadership provide a strong foundation for future growth. Investors should weigh the company’s strengths and risks carefully, but Beyond Air represents a compelling opportunity in the medical device and biopharmaceutical sectors.